Atlas Antibodies, a global developer of advanced reagents for biomedical research based in Sweden, has agreed to acquire Evitria Group from its shareholders. The transaction closed on August 5, 2021. Vischer advised the sellers on this
Tags :Vischer
Rigeto portfolio company Swissphone acquires instaSolution, a provider of modern and efficient communication and management solutions in the areas of alerting, crisis management, mobile collaboration, messaging and IoT. The transaction closed on July 16, 2021. Vischer
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
International hotel group Meininger manages its successful market entry in Switzerland and opens new hotels in Zürich Greencity (174 rooms, 582 beds) and Genève Centre Charmilles (104 rooms, 362 beds). Vischer advises Meininger on any Swiss
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
Vischer has acted as legal counsel to TargImmune Therapeutics, a private Swiss-based biotechnology firm, on the closing of its 2021 financing round, raising CHF 17.7 million. The Vischer legal team was led by Matthias Staehelin (pictured) with
Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Dermavant Sciences, a clinically focused biopharmaceutical company dedicated to developing and commercializing innovative therapies in the field of immune dermatology, has signed a $160 million revenue interest purchase and sale agreement with three participants for its
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as